Clinical Trial Update: Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating asciminib in combination with standard-of-care as maintenance therapy after allogeneic stem cell transplant in patients with P…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia in Blast Crisis
• Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Drugs mentioned

• Asciminib (asciminib)

Snippet

Sponsor: The University of Hong Kong | Conditions: Ph+ Acute Lymphoblastic Leukemia (Ph+ALL), Blastic Transformation of Chronic Myeloid Leukemia | Phase 2 | Status: NOT_YET_RECRUITING